Round Two: Mevacor Switch Will Need To Quiet Undertreatment Questions
This article was originally published in The Tan Sheet
Executive Summary
One of J&J/Merck's key challenges in pursuing an OTC switch for Mevacor (lovastatin) will be convincing FDA that labeling can alleviate the risk of undertreating high cholesterol